{"prompt": "['44', 'MC1488 WEE1', 'MCCC', '10.5', 'Other Required Reporting', '10.51', 'Persistent or Significant Disabilities/Incapacities', 'Any AE that results in persistent or significant incapacity or substantial disruption of the', 'ability to conduct normal life functions (formerly referred to as disabilities), congenital', 'abnormities or birth defects, must be reported immediately if they occur at any time', 'following treatment with an agent under an IND/IDE since they are considered to be', 'a', 'serious AE and must be reported to SRCI database as specified in 21 CFR 312.64(b).', '10.52', 'Death', 'Any death occurring within 30 days of the last dose, regardless of', 'attribution to an agent/intervention under an IND/IDE requires', 'expedited reporting within 24-hours.', 'Any death occurring greater than 30 days with an attribution of', 'possible, probable, or definite to an agent/intervention under an', 'IND/IDE requires expedited reporting within 24-hours.', 'Reportable categories of Death', 'Death attributable to a CTCAE term.', 'Death Neonatal: A disorder characterized by cessation of', 'life during the first 28 days of life.', 'Death NOS: A cessation of life that cannot be attributed to a', 'CTCAE term associated with Grade 5.', 'Sudden death NOS: A sudden (defined as instant or within', 'one hour of the onset of symptoms) or an unobserved', 'cessation of life that cannot be attributed to a CTCAE term', 'associated with Grade 5.', 'Death due to progressive disease should be reported as Grade', '5 \"Neoplasms benign, malignant and unspecified (incl', 'cysts and polyps) - Other (Progressive Disease)\" under the', 'system organ class (SOC) of the same name. Evidence that', 'the death was a manifestation of underlying disease (e.g.,', 'radiological changes suggesting tumor growth or progression:', 'clinical deterioration associated with a disease process)', 'should be submitted.', '10.53', 'Secondary Malignancy', 'A secondary malignancy is a cancer caused by treatment for a', 'previous malignancy (e.g., treatment with investigational', 'agent/intervention, radiation or chemotherapy). A secondary', 'malignancy is not considered a metastasis of the initial neoplasm.']['45', 'MC1488 WEE1', 'MCCC', 'All secondary malignancies that occur following treatment with an', 'agent under an IND/IDE must be reported.', 'Any malignancy possibly related to cancer treatment should also be', 'reported via the routine reporting mechanisms outlined in each protocol.', '10.54', 'Second Malignancy', 'A second malignancy is one unrelated to the treatment of a prior', 'malignancy (and is NOT a metastasis from the initial malignancy).', 'Second malignancies require ONLY routine reporting:', '10.55', 'Pregnancy', 'To ensure patient safety, each pregnancy occurring while the patient is on study', \"treatment and for up to 20 months from the patient's last dose must be reported\", 'to the SRCI Database within 24 hours of learning of its occurrence. The', 'pregnancy should be followed up to determine outcome, including spontaneous', 'or voluntary termination, details of the birth, and the presence or absence of any', 'birth defects, congenital abnormalities, or maternal and/or newborn', 'complications.', 'Pregnancy should be recorded on a Clinical Study Pregnancy Form and reported', 'by the investigator to SCRI Safety Database. Pregnancy follow-up should be', 'recorded on the same form and should include an assessment of the possible', 'relationship to the AstraZeneca study drug of any pregnancy outcome. Any SAE', 'experienced during pregnancy must be reported on the SAE Report Form.', 'In addition, each pregnancy occurring for a female partner of a male study', 'participant must be reported while the patient is on study treatment and for up', 'to', \"6 months after the patient's last dose. Pregnancy outcomes must be collected for\", 'the female partners of any males who took study treatment in this study. Consent', 'to report information regarding these pregnancy outcomes should be obtained', 'from the mother.', '10.6', 'Required Routine Reporting', 'Adverse events to be graded at each evaluation and pretreatment symptoms/conditions to', 'be evaluated at baseline per the CTCAE v4.0 grading unless otherwise stated in the table', 'below:', 'Each', 'System Organ Class', 'Adverse event/Symptoms', 'Baseline', 'evaluation', '(SOC)', 'General disorders and', 'Fatigue', 'X', 'X', 'administrations site', 'Fever (Pyrexia)', 'X', 'X', 'conditions', 'Blood and lymphatic', 'Anemia', 'X', 'X', 'system disorders', 'Gastrointestinal', 'Nausea', 'X', 'X', 'Disorders', 'Vomiting', 'X', 'X', '# of stools', 'X', 'Diarrhea', 'X']\n\n###\n\n", "completion": "END"}